Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment.
The objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies
patient with hematological malignancy (lymphoma, ALL, MM)
patient integrated into a CAR-T Cells program treatment
patient aged 15 years or over
patient having signed a written consent; as well as his legal representative if <18 years old
patient with other hematological malignancies than lymphoma, LAL or MM
patient's weight <58 kg
patient treated with another treatment than CAR-T Cells
patient under tutorship or curatorship
Patients with hematological malignancy
Cohort
Prospective
Not listed
Complete response rate
Overall Survival rate
Objective response rate
Objective response rate
Objective response rate
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
